Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Transcript

Why It Matters

Biogen’s earnings illustrate a pivotal transition from a declining MS franchise to a diversified growth‑product platform, shaping its future revenue trajectory and investor outlook.

Key Takeaways

• Non‑GAAP EPS $15.28, beating expectations
• Growth products revenue $3.3B, up 19% YoY
• MS product revenue set to decline mid‑teens 2026
• Lecanemab subcutaneous PDUFA scheduled May 24, 2026
• Cash $4.2B, net debt $2B, strong balance sheet

Pulse Analysis

Biogen’s fourth‑quarter earnings underscore a company at a strategic inflection point. While total revenue edged up only 2% to $9.9 billion, the modest top‑line growth masks a stark contrast between legacy multiple‑sclerosis (MS) erosion and the rapid ascent of newer assets. Non‑GAAP diluted EPS of $15.28 topped analyst forecasts, reflecting disciplined cost control and the scaling of high‑margin products. However, management warned that MS sales—excluding VUMERITY—will contract by a mid‑teen percentage in 2026, driven by generic Tecfidera erosion and biosimilar competition for Tysabri. This headwind underscores the urgency of diversifying the revenue mix.

The engine of Biogen’s future growth lies in its expanding portfolio of recently launched therapies. VUMERITY, SKYCLARIS, ZERZUVE and CALSADI together generated over $1 billion in 2025, with SKYCLARIS revenue jumping 30% YoY and ZERZUVE doubling sales. The company’s pipeline now features ten Phase 3 programs, highlighted by the subcutaneous formulation of LECANEMAB—targeting Alzheimer’s—with a PDUFA decision slated for May 24, 2026, and a high‑dose SPINRAZA filing due in April. Strategic acquisitions, such as Alcion Therapeutics, and collaborations with Vanqua and Dara Therapeutics, further broaden Biogen’s injection‑delivery expertise and pipeline depth, positioning it to capture emerging market opportunities.

Looking ahead, Biogen’s financial flexibility—$4.2 billion in cash and marketable securities against $2 billion net debt—provides a runway for continued R&D investment, potential share repurchases, or selective M&A. With operating expenses expected to remain flat and gross margins projected to hold steady, the company’s upside hinges on the successful commercialization of its growth products and the timely approval of pipeline assets. Investors will be watching the 2026 revenue guidance closely, balancing the anticipated decline in legacy MS sales against the scaling potential of high‑margin, next‑generation therapies.